Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for FAGR.BR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FAGR.BR and 80,000+ other tickers.
See exactly how FAGR.BR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FAGR.BR and 80,000+ other tickers.
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs…
No recent news available.